Com­put­er sci­ence and en­gi­neer­ing, meet drug R&D. MIT star Tim­o­thy Lu in­ter­twines tech­nolo­gies for an off­beat biotech launch

At 37, Tim­o­thy Lu’s life and work has al­ready spanned sev­er­al sci­en­tif­ic dis­ci­plines and cul­tures. He’s lived in Asia and the US, and af­ter gath­er­ing de­grees in elec­tri­cal en­gi­neer­ing and com­put­er sci­ence at MIT, he struck out to pick up his med­ical de­gree at Har­vard Med and then a PhD at the Har­vard-MIT Health Sci­ences and Tech­nol­o­gy Med­ical En­gi­neer­ing and Med­ical Physics Pro­gram.

Knit­ting that all to­geth­er at the Syn­thet­ic Bi­ol­o­gy Group at MIT, Lu has be­come one of the pi­o­neers in the field, tack­ling dis­ease by cre­at­ing a ge­net­ic cir­cuit pro­gram­ming plat­form that could one day start fix­ing the er­rant code in our ge­net­ics that trig­gers dis­ease.

Af­ter help­ing found a va­ri­ety of dif­fer­ent star­tups, Lu’s fas­ci­na­tion with adap­tive ther­a­pies is push­ing him to launch a new biotech which is com­ing out for its first pub­lic bow af­ter rais­ing $53 mil­lion to cre­ate next-gen cell and gene ther­a­pies at a start­up dubbed Sen­ti Bio­sciences.

Lu is once again on the move, re­lo­cat­ing on sab­bat­i­cal to take the helm of the start­up in the Bay Area as its found­ing CEO. He’s work­ing along­side co-founder Philip Lee, a bio­engi­neer­ing ex­pert with a Berke­ley PhD and an en­tre­pre­neur­ial record at Cel­lA­SIC, a mi­croflu­idics ven­ture which was snapped up by Mer­ck KGaA. Long­time men­tor and MIT pro­fes­sor Jim Collins — who helped found Syn­log­ic with Lu — is along for the ride. And cell en­gi­neer­ing ex­pert Wil­son Wong out of Boston Uni­ver­si­ty is al­so of­fer­ing in­put on the sci­ence.

“I’ve been work­ing in this area for quite a while,” says Lu. “The field re­al­ly has evolved over the past 18 years. We are at the point where we can build fair­ly so­phis­ti­cat­ed ge­net­ic con­structs.”

Fur­ther out on the time hori­zon, it may be pos­si­ble to one day cre­ate a net­work of dis­ease sen­sors that could trig­ger a re­sponse that would stop dis­ease be­fore it ever be­gins. But Lu and his team are acute­ly aware that they’re in the prac­ti­cal prod­uct con­struc­tion phase, build­ing on ear­li­er work that, for in­stance, in­volved de­vel­op­ing an im­munomod­u­la­to­ry gene cir­cuit plat­form that “en­ables tu­mor-spe­cif­ic ex­pres­sion of im­munos­tim­u­la­tors” which could over­come the lim­i­ta­tions of anti­gen dri­ven ther­a­pies.

Lu stress­es that he has his eye on fil­ing an IND in the not too dis­tant fu­ture. Along the way he’d like to at­tract phar­ma part­ners. And the core team of 20 will now ex­pand to close to 40 staffers.

“Our goal is to pur­sue clin­i­cal ap­pli­ca­tions, move to­ward an IND,” he says. And they have the fund­ing to get a lead can­di­date and get close to en­ter­ing the clin­ic in the next 2.5 to 3 years.

The team brings to­geth­er sci­en­tists and ad­vi­sors that al­so span nu­mer­ous fields, com­ing from MIT, the Wyss In­sti­tute at Har­vard, MD An­der­son, Boston Uni­ver­sityand ETH Zurich. His syn­di­cate al­so re­flects an un­usu­al blend of bio­phar­ma and some tech in­vestors you usu­al­ly don’t find mix­ing in the drug de­vel­op­ment world. New En­ter­prise As­so­ci­ates led the round, with par­tic­i­pa­tion from 8VC, Am­gen Ven­tures, Pear Ven­tures, Lux Cap­i­tal, Men­lo Ven­tures, Allen & Com­pa­ny, Nest.Bio, Omega Funds, Good­man Cap­i­tal, and Life­Force Cap­i­tal.

“De­sign­ing ge­net­ic cir­cuits is not easy,” Lu tells me. “It re­quires a lot of en­gi­neer­ing and plat­form build­ing to build, test and learn.” The au­toma­tion and com­pu­ta­tion­al tools need­ed to make it work was the kind of sto­ry that res­onat­ed with tech in­vestors, he adds.

In the mean­time, his broth­er Jef­frey is al­so at work in the Bay Area build­ing En­gine Bio­sciences, which will fo­cus more on nat­ur­al ge­net­ic cir­cuits while Tim­o­thy Lu stays fo­cused more on syn­thet­ic tech.


Im­age: Tim­o­thy Lu. MIT CAM­PAIGN FOR A BET­TER WORLD

Grow­ing ac­cep­tance of ac­cel­er­at­ed path­ways for nov­el treat­ments: but does reg­u­la­to­ry ap­proval lead to com­mer­cial suc­cess?

By Mwango Kashoki, MD, MPH, Vice President-Technical, and Richard Macaulay, Senior Director, of Parexel Regulatory & Access

In recent years, we’ve seen a significant uptake in the use of regulatory options by companies looking to accelerate the journey of life-saving drugs to market. In 2018, 73% of the novel drugs approved by the U.S. Federal Drug Administration (FDA) were designated under one or more expedited development program categories (Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval).ᶦ

Take­da swoops in to buy lit­tle biotech part­ner and its celi­ac drug poised to 'change stan­dard of care'

Having spent three years carefully grooming PvP Biologics and its drug for celiac disease, Takeda is happy enough with the proof-of-concept data to buy it all.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 73,100+ biopharma pros reading Endpoints daily — and it's free.

Bio­gen touts new ev­i­dence from the gene ther­a­py com­pa­ny it wa­gered $800M on

A year ago, Biogen made a big bet on a small gene therapy company. Now they have new evidence one of their therapies could work.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 73,100+ biopharma pros reading Endpoints daily — and it's free.

Mi­cro­bio­me Q&A: New study maps the vagi­na's 'op­ti­mal mi­cro­bio­ta' — and its im­pli­ca­tions for bio­phar­ma

The widely-held notion that the “optimal” vaginal microbiota is dominated by one strain of lactic-acid producing bacteria has now been challenged in a new paper, published in Nature Communications on Wednesday, which used advanced gene sequencing methods to map out the most comprehensive gene catalog of the human vaginal microbiome.

Things have changed in the more than 50 years since the concept of vaginal microbiota transplants was proposed and subsequently tainted by a Texas-based gynecologist who transplanted the vaginal fluid of women who had bacterial vaginosis into healthy females, suspecting he had isolated the bacteria responsible for the condition.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 73,100+ biopharma pros reading Endpoints daily — and it's free.

In at least one life-sci hub, gen­der and di­ver­si­ty ini­tia­tives haven’t made a dent

Gender and racial diversity at the top of UK life science companies has hardly budged over the last seven years despite repeated advocacy efforts, according to a new report.

The report, from the recruiting firm Liftstream, found that 14.8% of directors on life sciences boards were women and 21.1% of top executives were women. That’s a modest bump from the 9.8% of directors and 18.1% of executives Liftstream identified in their last report from 2014. The percentage of women CEOs moved from 8% to 9.8%.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 73,100+ biopharma pros reading Endpoints daily — and it's free.

Will a 'risk-of­f' mind­set has­ten cell ther­a­py M&A? Io­vance surges on buy­out chat­ter

Is it time for some cell therapy M&A?

Investors of Iovance Biotherapeutics certainly thought so, sending its stock $IOVA up as much as 40% after Bloomberg reported that the cancer-focused biotech is talking to potential buyers.

While 2019 saw a number of high-profile gene therapy company takeovers — led by Roche’s $4.3 billion bid of Spark as Astellas went for Audentes, Biogen snapped up Nightstar and Vertex absorbed Exonics — large players appeared to prefer partnering on the cell therapy front, particularly when it comes to cancer. Hal Barron put his weight behind Rick Klausner’s startup as he rebuilt GlaxoSmithKline’s cancer pipeline. Takeda turned to MD Anderson to license their natural killer cell therapy.

One less ri­val for Im­muno­vant, as Alex­ion aban­dons FcRn in­hibitor

Less than one year after Alexion parted with $25 million upfront to secure access to a second anti-FcRn asset, it is abandoning the experimental drug. The discontinuation, disclosed at the SVB Leerink Global Healthcare Conference in New York during a fireside chat, bodes well for rival Immunovant.

The drug (ABY-039), partnered for development with Sweden’s Affibody, was forsaken on the basis of early-stage data that was not viewed favorably, Baird and SVB Leerink analysts noted.

Clin­i­cal tri­al spon­sors have to dis­close decade’s worth of un­re­leased da­ta, fed­er­al judge rules

A decade’s worth of unreleased trial data may soon see the light of day.

A New York federal judge ruled this week that the FDA and the NIH have for years misinterpreted a law that would require companies, universities and other clinical trial sponsors to release trial data from studies completed between 2007 and 2017. The ruling covers drugs and medical devices that were experimental when the study was completed but have since been approved, potentially putting hundreds of sponsors out of compliance if they don’t put their results on clinicaltrials.gov.

Laurie Glimcher and Ansbert Gadicke (Justin Knight, Dana-Farber Cancer Institute)

Ty­ing ba­sic sci­ence to spin­outs, Dana-Far­ber de­buts sis­ter funds to­tal­ing $126M with MPM Cap­i­tal

As one of the most prestigious cancer institutes in the US, Dana-Farber has enjoyed considerable support for its entrepreneurial pursuits, spinning out about 30 companies in the past 12 years.

“Now where we’ve always struggled — where every cancer center struggled — is support of basic science,” Barrett Rollins, chief scientific officer emeritus, told Endpoints News.

And then two of its trustees had an idea. What if they tied philanthropy to investment in Dana-Farber startups, requiring a donation to basic science as a condition for accessing its brightest biotech venture ideas?